Edition:
United Kingdom

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

28.13USD
22 Jun 2018
Change (% chg)

$0.50 (+1.81%)
Prev Close
$27.63
Open
$28.24
Day's High
$28.74
Day's Low
$27.75
Volume
1,328,188
Avg. Vol
199,086
52-wk High
$28.74
52-wk Low
$14.24

Chart for

About

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs... (more)

Overall

Beta: --
Market Cap(Mil.): $1,473.30
Shares Outstanding(Mil.): 68.30
Dividend: --
Yield (%): --

Financials

  DPLO.N Industry Sector
P/E (TTM): 119.82 28.41 32.74
EPS (TTM): 0.18 -- --
ROI: 1.25 6.42 14.38
ROE: 1.98 10.07 16.08

BRIEF-Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18

* DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE

26 Feb 2018

BRIEF-Diplomat Pharmacy Says Dispensing Advanced Kidney Treatment, CABOMETYX

* DIPLOMAT PHARMACY INC - ‍IS DISPENSING EXELIXIS' LIMITED-DISTRIBUTION TREATMENT CABOMETYX NOW WITH AN EXPANDED INDICATION​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

15 Jan 2018

BRIEF-Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook

* DIPLOMAT PHARMACY INC - ‍JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY​

05 Jan 2018

BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

* - EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE

05 Jan 2018

Competitors

Earnings vs. Estimates